AVITA Medical (ASX:AVH): Q2 2026 Results and RECELL Commercial Priorities

Aditi Sarkar

03 November 2026 05:53 PM AEDT

AVITA Medical (ASX:AVH): Q2 2026 Results and RECELL Commercial Priorities

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

AVITA reported 18% year-on-year Revenue growth in Q2 2026.
Second-quarter operating expenses were USD 24.6 million, down 6% year on year.
Q2 net cash use was approximately USD 3.2 million.
The company scheduled its third-quarter 2026 results for 5 November 2026 US time.

AVITA Medical Inc (ASX:AVH) develops and distributes products for acute wound care, including the RECELL system for preparing spray-on skin cells from a patient’s own skin. On 3 November 2026, the stock finished the session at AUD 4.32. The company’s recent 2026 disclosures bring its operational priorities and financial measures into focus.

Second-Quarter Financial Update

AVITA Medical (ASX:AVH) reported second-quarter 2026 revenue growth of 18% year on year and 13% sequentially. Operating expenses were USD 24.6 million, down 6% from the corresponding quarter. Net cash use was approximately USD 3.2 million, compared with USD 9.9 million in the first quarter, while cash, cash equivalents and marketable securities were approximately USD 11.1 million at quarter-end.

The company raised its full-year 2026 net revenue guidance to USD 86 million to USD 89 million in its August release. Guidance is an expression of management expectations, not an achieved result. The release also described an expectation of fourth-quarter cash-flow break-even. That statement depends on actual collections, inventory, operating spending and the progress of commercial sales.

Product Portfolio and Upcoming Reporting

RECELL is the central product in AVITA Medical’s acute wound care portfolio, with applications in thermal burn and trauma wounds under applicable approvals. The company also markets Cohealyx and PermeaDerm products in the United States under stated distribution arrangements. These products address different aspects of wound treatment, so sales and use must be interpreted within their own indications and commercial arrangements.

AVITA (ASX:AVH) announced on 20 October that its third-quarter 2026 financial results would be released on 5 November 2026 after the US market close. As of 3 November, those results were not yet scheduled to be publicly released. Upcoming reporting will help distinguish second-quarter performance from any subsequent changes in demand, costs or cash consumption.

Operating Risks and Financial Context

For AVITA Medical Inc (ASX:AVH), the most useful assessment separates Business activity from financial outcomes. The distinction between an announced milestone and a completed commercial or financial outcome is important. Management disclosures can describe objectives, progress and planned next steps, but reported results provide the evidence of what was achieved during a particular period. Comparing successive reporting periods on the same accounting or operational basis helps avoid misleading conclusions. Sector-wide conditions can influence a business without demonstrating that they caused a particular daily share-price movement.

What to Watch Next

Important areas for the next published updates include Q3 revenue and cash use, actual performance against full-year guidance, product utilisation and reimbursement developments. Each may affect the interpretation of the company’s progress, but none should be treated as a forecast of profitability, trial success or share-price performance. The timing of disclosures also matters because the information available at 3 November 2026 may not cover every development later in the financial year.

Key Insights

AVITA Medical Inc (ASX:AVH) has reported developments during 2026 that relate to its operating model, financial resources and management priorities. Its latest disclosed measures need to be interpreted on their stated reporting basis. The next company updates may clarify the pace of activity, associated costs and the extent to which operational progress translates into recognised revenue, clinical evidence or available cash, as relevant to the business.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.